CompletedNot applicableNCT01439854
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Studying Multiple mitochondrial dysfunctions syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Principal Investigator
- Ralph DeFronzo, MD, M.DThe University of Texas Health Science Center at San Antonio
- Intervention
- Dapagliflozin(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2011 – 2018
Study locations (1)
- Diabetes Division, UTHSCSA, San Antonio, Texas, United States
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01439854 on ClinicalTrials.gov